The Food and Drug Administration on Thursday granted accelerated approval to a new dual-acting drug from Amgen to treat small cell lung cancer in people whose disease has progressed following ...
The U.S. Food and Drug Administration approved on Tuesday Amgen's Bkemv, the first biosimilar to AstraZeneca's rare blood ...
La Food and Drug Administration des États-Unis a approuvé mardi le Bkemv d'Amgen, le premier biosimilaire de Soliris, le traitement d'AstraZeneca contre les maladies sanguines rares.
La Food and Drug Administration des États-Unis a accordé une autorisation accélérée au tarlatamab, l'immunothérapie ciblée ...
The US FDA has approved Amgen's Bkemv as an interchangeable biosimilar to Soliris for the treatment of specific rare diseases ...
The U.S. Food and Drug Administration on Thursday granted accelerated approval to Amgen's tarlatamab, a targeted ...
Amgen Inc. (NASDAQ:AMGN) has recently been in the news due to its involvement in the promising obesity drug market. Analysts ...
FRIDAY, MAY 17, 2024 (HealthDay News) -- The U.S. Food and Drug Administration on Thursday approved a new drug to treat ...
Pharmaceutical stock Amgen (AMGN) is rising following early positive results from the development of its new GLP-1 weight-loss drug, MariTide. Yahoo Finance Senior Health Reporter Anjalee Khemlani ...
The FDA has made two approvals this week: the first interchangeable biosimilar of Soliris and another indication for Breyanzi for mantel cell lymphoma. The agency has delay a decision on Dupixent in ...
The Food and Drug Administration last week approved an innovative new treatment for patients with a form of lung cancer. It ...